XML 47 R37.htm IDEA: XBRL DOCUMENT
v3.25.3

Subsequent events | 12 Months Ended
--- | ---
Jun. 30, 2025
Disclosure [Abstract] |
Subsequent events | Note 30. Subsequent events Fundraising Activities From July 2025 through October 2025, the Consolidated Entity raised net proceeds of US$ 1,397,016 (A$ 2,112,090 ) using the ATM facility and the company executed a private placement of equity securities (PIPE), raising US$ 2,049,992 (A$ 3,169,546 ) and continues to seek additional funding sources both in Australia and overseas. Licensing Activities On 7 October 2025, the company announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD- L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a new and innovative frontier of cancer immunotherapy. No other matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the Consolidated Entity’s operations, the results of those operations, or the Consolidated Entity’s state of affairs in future financial years

X
- Definition The entire disclosure for events after the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 10 -IssueDate 2025-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | kzia_DisclosureAbstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration